Trial Profile

A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, PK, and PD of BMF-219, an Oral Covalent Menin Inhibitor, in Healthy Adults and Adults With T2DM

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 14 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Icovamenib (Primary)
Indications Type 2 diabetes mellitus
Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
Acronyms COVALENT-111
Sponsors Biomea Fusion

03 Jul 2025 Planned End Date changed from 1 May 2025 to 1 Jul 2025.
23 Jun 2025 According to a Biomea Fusion media release, data from this study presented as a late breaking poster presentation at the 85th Scientific Sessions of the American Diabetes Association (ADA) June 20-23, 2025 in Chicago.
23 Jun 2025 Results presented in the Biomea Fusion Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com